In the last two decades, PSMA (a 750–amino acid type II transmembrane glycoprotein) has been demonstrated as a potential diagnostic and therapeutic target for PCa (O'Keefe et al., 2018). This evidence concerns the gene FOLH1 and posterior cortical atrophy.